Calendar
April 18 – 22, 2015
April 20 – 22, 2015
2015 American Association for Cancer
Research Annual Meeting
British Society of Hematology Annual
Scientific Meeting
Philadelphia, PA
The AACR Annual Meeting 2015 will highlight the latest
discoveries in every area of cancer research. This year’s
meeting theme is “Bringing Cancer Discoveries to
Patients.”
Edinburgh, Scotland, UK
The 55th Annual Scientific Meeting gathers the British
hematology community to network and discuss the
changing clinical and laboratory practice landscape, as
well as report on advances in the field. The theme of this
year’s meeting is “improving outcomes.”
Philadelphia city scape as seen from the Benjamin Franklin Bridge
Summary of Prescribing Information
BLINCYTO™ (blinatumomab)
for injection, for intravenous use
WARNING: CYTOKINE RELEASE SYNDROME and
NEUROLOGICAL TOXICITIES
observed in approximately 25% of patients, some of which
were life-threatening or fatal. As appropriate, administer
prophylactic antibiotics and employ surveillance testing
during treatment with BLINCYTO™. Monitor patients for
signs and symptoms of infection and treat appropriately.
5.4 Tumor Lysis Syndrome
• Cytokine Release Syndrome (CRS), which may be lifethreatening or fatal, occurred in patients receiving
BLINCYTO™. Interrupt or discontinue BLINCYTO™
as recommended. [See Dosage and Administration
(2.3), Warnings and Precautions (5.1)].
• Neurological toxicities, which may be severe, lifethreatening, or fatal, occurred in patients receiving
BLINCYTO™. Interrupt or discontinue BLINCYTO™ as
recommended. [See Dosage and Administration (2.3),
Warnings and Precautions (5.2)].
Tumor lysis syndrome (TLS), which may be life-threatening
or fatal, has been observed in patients receiving
BLINCYTO™.
Appropriate prophylactic measures,
including pretreatment nontoxic cytoreduction and ontreatment hydration, should be used for the prevention
of TLS during BLINCYTO™ treatment. Monitor for signs
or symptoms of TLS. Management of these events may
require either temporary interruption or discontinuation of
BLINCYTO™ [see Dosage and Administration (2.3)].
1.
Neutropenia and febrile neutropenia, including lifethreatening cases, have been observed in patients receiving
BLINCYTO™. Monitor laboratory parameters (including,
but not limited to, white blood cell count and absolute
neutrophil count) during BLINCYTO™ infusion. Interrupt
BLINCYTO™ if prolonged neutropenia occurs.
INDICATIONS AND USAGE
BLINCYTO™ is indicated for the treatment of Philadelphia
chromosome-negative relapsed or refractory B-cell
precursor acute lymphoblastic leukemia (ALL).
This indication is approved under accelerated approval.
Continued approval for this indication may be contingent
upon verification of clinical benefit in subsequent trials [see
Clin